Clinical Trial

A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

Study acronym: Elevate-CKD
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled multicenter study to investigate outcomes with elecoglipron compared with placebo in participants with CKD with and without T2DM who are on background SGLT2i (dapagliflozin) as GDMT and other SoC treatments for CKD.
Trial Details
NCT Number NCT07753993
Lead Sponsor AstraZeneca
Conditions Chronic Kidney Disease
Enrollment 7,000 participants
Start Date 2026-08-28
Primary Completion 2030-10-04 (estimated)
Study Completion 2030-10-04 (estimated)
Updated on ClinicalTrials.gov 2026-08-10